|
시장보고서
상품코드
2008170
인간 배아줄기세포 시장 : 제품별, 지역별Human Embryonic Stem Cells Market, By Product (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing) , By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) |
||||||
인간 배아줄기세포(인간 ES 세포) 시장은 2026년에 15억 달러로 추정되고 있으며, 2033년까지 21억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 9.72%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 15억 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 9.72% | 예측 금액(2033년) | 21억 달러 |
줄기세포는 다른 유형의 세포로 분화할 수 있는 생물학적 세포로, 치료 목적으로 사용됩니다. 최근 동향과 기술 혁신은 수많은 잠재적 치료법의 길을 열어주었고, 그 결과 인간 배아줄기세포를 이용한 치료법이 전 세계에서 널리 채택되고 있습니다. 인간 배아줄기세포는 잃어버린 세포와 조직의 기능을 회복시킬 수 있는 세포치료에 있으며, 유망한 후보로 떠오르고 있습니다. 또한 인간배아줄기세포(hESC)는 치료 적용 가능성이 높아 심장질환 및 악성질환의 표준치료제가 될 가능성이 높다.
시장 역학
심장 질환 및 악성 질환의 발병률 증가, 줄기세포를 이용한 치료법 개발에 대한 관심 증가, 재생의료에 대한 수요 증가, 정부 및 민간 기관의 지원 증가는 예측 기간 중 글로벌 인간 배아줄기세포 시장의 성장을 촉진할 것으로 예상되는 주요 요인입니다.
예를 들어 2021년 4월 Vertex Pharmaceuticals는 미국 식품의약국(FDA)으로부터 VX-880에 대한 패스트트랙 지정을 받아 중증 저혈당 및 저혈당 인식 장애를 동반한 제1형 당뇨병 환자를 대상으로 한 VX-880의 임상시험을 시작했습니다.
2020년 2월, 글로벌 줄기세포 치료 및 연구 기관(GIOSTAR)은 인도에 새로운 줄기세포 및 암 연구 및 치료 센터를 개설했다고 발표했습니다. 이 시설은 인도, 멕시코, 미국 및 기타 여러 국가에서 지오스타가 주도하고 있는 글로벌 확장 노력의 최신 이정표가 될 것입니다.
이 보고서의 주요 특징
- 세계의 인간 배아줄기세포 시장을 상세히 분석하고, 2025년을 기준연도로 하여 예측기간(2026-2033년) 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트를 제공합니다.
- 세계 인간 배아줄기세포 시장의 주요 기업 개요을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 매개 변수를 기반으로 정리하여 수록했습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계의 인간 배아줄기세포 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 인간배아줄기세포 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 인간 배아줄기세포 시장 : 제품별(2026-2033년)
제5장 세계의 인간 배아줄기세포 시장 : 지역별(2026-2033년)
제6장 경쟁 구도
제7장 섹션
KSA 26.05.04Human Embryonic Stem Cells Market is estimated to be valued at USD 1.5 Bn in 2026 and is expected to reach USD 2.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.72% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.72% | 2033 Value Projection: | USD 2.1 Bn |
Stem cells are biological cells that can differentiate into other types of cells, and are used for therapeutic purposes. Recent developments or advancements have paved the way for a plethora of potential therapies, due to which, therapies involving human embryonic stem cells are being widely adopted worldwide. Human embryonic stem cells have emerged as attractive candidates for cell-based therapies that are capable of restoring lost cell and tissue function. Furthermore, human embryonic stem cells (hESC) have a high potential for use in treatment and may become a standard of care for cardiac and malignant diseases.
Market Dynamics
Rise in incidence of cardiac and malignant diseases, increase in focus on the development of stem cell-based therapies, growing demand for regenerative medicines, and increasing support from government and private organizations are major factors expected to drive growth of the global human embryonic stem cells market during the forecast period.
For instance, in April 2021, Vertex Pharmaceuticals received the United States Food and Drug Administration (FDA) Fast Track Designation for VX-880, and the company initiated a clinical trial for VX-880 in patients who have type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness.
In February 2020, Global Institute of Stem Cell Therapy and Research (GIOSTAR) announced the inauguration of a new stem cell / cancer research and therapy center in India. This facility represents the latest milestone in global expansion efforts spearheaded by GIOSTAR in India, Mexico, the United States, and numerous other countries.
Key features of the study
- The report provides in-depth analysis of the global human embryonic stem cells market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global human embryonic stem cells market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global human embryonic stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human embryonic stem cells market.
Market Segmentation
- By Product
- Regenerative Medicine
- Stem Cell Biology Research
- Tissue Engineering
- Toxicology Testing
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Takara Bio Inc.
- ViaCyte Inc.
- PromoCell GmbH
- Merck KgaA
- PeproTech Inc.
- Astellas Pharma Inc.
- Thermo Fisher Scientific
- Lineage Cell Therapeutics Inc.
- STEMCELL Technologies Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Human Embryonic Stell Cells Market, By Product, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- Regenerative Medicine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Stem Cell Biology Research
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Tissue Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Toxicology Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
5. Global Human Embryonic Stell Cells Market, By Region, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
6. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Takara Bio Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- ViaCyte Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PromoCell GmbH
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck KgaA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PeproTech Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lineage Cell Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- STEMCELL Technologies Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
7. Section
- References
- Research Methodology
- About Us
